Biotech
IDM Pharma(IDMI) soared in after-hours trading Thursday after announcing it presented more positive late-stage trial data for Mifamurtide.
The biopharmaceutical company said it presented updated data from a phase III clinical trial of Mifamurtide (formerly called Junovan) added to chemotherapy to treat osteosarcoma, a rare and often fatal bone tumor in children and young adults. The data, based on long-term follow-ups with patients originally treated in the phase III trial, confirmed that the combination achieved statistically significant overall survival rates. In July, IDM agreed to submit additional data for Mifamurtide to the FDA. The company is in the process of amending a new-drug application for the drug with the long-term survival data. Shares rose 29 cents, or 20.9%, to $1.68, in recent after-hours trading.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 16.25 |
Oil *
103.00
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |
Connect with TheStreet